These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 10785469)

  • 1. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
    Chi DS; Venkatraman ES; Masson V; Hoskins WJ
    Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.
    Obeidat B; Latimer J; Crawford R
    Gynecol Obstet Invest; 2004; 57(3):153-6. PubMed ID: 14726621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer.
    Gemer O; Segal S; Kopmar A
    Acta Obstet Gynecol Scand; 2001 Jun; 80(6):583-5. PubMed ID: 11380298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epithelial ovarian cancer--preoperative assessment of Ca 125 levels as an independent prognostic factor].
    Ivanov S; Ivanov S
    Akush Ginekol (Sofiia); 2003; 42(3):16-9. PubMed ID: 12858485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
    Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
    Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer.
    Gemer O; Lurian M; Gdalevich M; Kapustian V; Piura E; Schneider D; Lavie O; Levy T; Fishman A; Dgani R; Levavi H; Beller U
    Eur J Surg Oncol; 2005 Nov; 31(9):1006-10. PubMed ID: 16005601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with cytoreducibility among women with ovarian carcinoma.
    Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K; Morgan A
    Gynecol Oncol; 2004 Nov; 95(2):377-83. PubMed ID: 15491760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
    Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
    Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
    Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma.
    Leitao M; Boyd J
    Gynecol Oncol; 2002 Mar; 84(3):413-5. PubMed ID: 11855879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
    Rossi AC; Di Vagno G; Cormio G; Cazzolla A; Stefanelli S; D'Elia E; Selvaggi L
    Arch Gynecol Obstet; 2004 May; 269(4):263-5. PubMed ID: 14745561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases.
    Naik R; Nordin A; Cross PA; Hemming D; de Barros Lopes A; Monaghan JM
    Gynecol Oncol; 2000 Aug; 78(2):171-5. PubMed ID: 10926798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma.
    de Jong D; Eijkemans MJ; Lie Fong S; Gerestein CG; Kooi GS; Baalbergen A; van der Burg ME; Burger CW; Ansink AC
    Oncology; 2007; 72(5-6):293-301. PubMed ID: 18198490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
    Bristow RE; Montz FJ
    Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis.
    Kang S; Kim TJ; Nam BH; Seo SS; Kim BG; Bae DS; Park SY
    J Surg Oncol; 2010 Jan; 101(1):13-7. PubMed ID: 20025071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?
    Saygili U; Guclu S; Uslu T; Erten O; Demir N; Onvural A
    Gynecol Oncol; 2002 Jul; 86(1):57-61. PubMed ID: 12079301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.
    Geisler JP; Miller GA; Lee TH; Harwood RM; Wiemann MC; Geisler HE
    J Reprod Med; 1996 Mar; 41(3):140-2. PubMed ID: 8778409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer.
    Cooper BC; Sood AK; Davis CS; Ritchie JM; Sorosky JI; Anderson B; Buller RE
    Obstet Gynecol; 2002 Jul; 100(1):59-64. PubMed ID: 12100804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
    Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
    Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.